| Product Code: ETC7659289 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Plasma Protease C1-inhibitor Treatment Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Plasma Protease C1-inhibitor Treatment Market - Industry Life Cycle |
3.4 Israel Plasma Protease C1-inhibitor Treatment Market - Porter's Five Forces |
3.5 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume Share, By Dosage Type, 2021 & 2031F |
3.7 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Plasma Protease C1-inhibitor Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of hereditary angioedema (HAE) in Israel |
4.2.2 Growing awareness about plasma protease C1-inhibitor treatment options |
4.2.3 Technological advancements in the development of C1-inhibitor therapies |
4.3 Market Restraints |
4.3.1 High cost associated with plasma protease C1-inhibitor treatments |
4.3.2 Limited availability of specialized healthcare facilities for administering C1-inhibitor therapies |
5 Israel Plasma Protease C1-inhibitor Treatment Market Trends |
6 Israel Plasma Protease C1-inhibitor Treatment Market, By Types |
6.1 Israel Plasma Protease C1-inhibitor Treatment Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By C1-inhibitors, 2021- 2031F |
6.1.4 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By C1-esterase Inhibitor, 2021- 2031F |
6.1.5 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Kallikrein Inhibitor (Kalbitor), 2021- 2031F |
6.1.6 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Selective Bradykinin B2 Receptor Antagonist (Firazyr), 2021- 2031F |
6.2 Israel Plasma Protease C1-inhibitor Treatment Market, By Dosage Type |
6.2.1 Overview and Analysis |
6.2.2 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Liquid/Injectable, 2021- 2031F |
6.2.3 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Lyophilized, 2021- 2031F |
6.3 Israel Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 Israel Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Independent Pharmacies and Outlets, 2021- 2031F |
7 Israel Plasma Protease C1-inhibitor Treatment Market Import-Export Trade Statistics |
7.1 Israel Plasma Protease C1-inhibitor Treatment Market Export to Major Countries |
7.2 Israel Plasma Protease C1-inhibitor Treatment Market Imports from Major Countries |
8 Israel Plasma Protease C1-inhibitor Treatment Market Key Performance Indicators |
8.1 Number of patients diagnosed with HAE opting for plasma protease C1-inhibitor treatment |
8.2 Percentage increase in healthcare professionals trained in administering C1-inhibitor therapies |
8.3 Rate of adoption of newly developed C1-inhibitor treatments |
9 Israel Plasma Protease C1-inhibitor Treatment Market - Opportunity Assessment |
9.1 Israel Plasma Protease C1-inhibitor Treatment Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Israel Plasma Protease C1-inhibitor Treatment Market Opportunity Assessment, By Dosage Type, 2021 & 2031F |
9.3 Israel Plasma Protease C1-inhibitor Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Plasma Protease C1-inhibitor Treatment Market - Competitive Landscape |
10.1 Israel Plasma Protease C1-inhibitor Treatment Market Revenue Share, By Companies, 2024 |
10.2 Israel Plasma Protease C1-inhibitor Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here